Abstract Library

#2152 Sequential Therapies in Well-Differentiated Gastrointestinal Neuroendocrine Tumors G3 (NET G3): Platinum-Based vs. Platinum-Free Regimens

Introduction: Well-differentiated NET G3 show a longer clinical course than NEC G3, preliminary data indicate they respond poorly to platinum-based therapies.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Dal Buono A

Authors: Dal Buono A, Merola E, Delle Fave G, Wiedenmann B, Pavel M,

Keywords: well-differentiated, platinum, streptozotocin,

#1785 Eterogeneity of Duodenal Neuroendocrine Tumors: A Multi-Centre Experience in Italy

Introduction: Duodenal neuroendocrine neoplasms (dNENs) are heterogeneous tumors, which could have a highly variable prognosis.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Rossi, Roberta Elisa r

Authors: Massironi S, Panzuto F, Rinzivillo M, Rossi R, Delle Fave G,

Keywords: duodenal neuroendocrine neoplasm, duodenum, gastrinoma, somatostatinoma, diagnosis, therapy guidelines,

#1540 FOLFOX Chemotherapy: Efficacy and Tolerability in Advanced Digestive Neuroendocrine Neoplasms (NENs)

Introduction: FOLFOX has been poorly investigated in digestive NEN (DNENs), mostly in small cohorts.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Dal Buono A, Merola E, Delle Fave G, Wiedenmann B, Pavel M,

Keywords: FOLFOX, tolerability, tumor response.,

#1533 Chromogranin A in the Follow-up of Digestive Neuroendocrine Neoplasms: Is It a Useful Biomarker?

Introduction: Chromogranin A (CgA) is the most frequently used biomarker in digestive neuroendocrine neoplasms (DNENs) but its real usefulness is still unclear

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Merola E, Delle Fave G, Blankenstein O, Wiedenmann B, Pavel M,

Keywords: CgA, clinical usefulness, ≥ 50% increase,

#1437 Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: A Subgroup Analysis of the Phase 3 RADIANT-4 Study

Introduction: In the phase 3, RADIANT-4 study, everolimus (EVE) improved median progression-free survival (PFS) by 7.1 months in patients (pts) with advanced, progressive, nonfunctional NET of lung or GI tract compared to placebo (PBO); HR, 0.48; 95%CI, 0.35-0.67; P<0.00001.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Fazio N

Authors: Fazio N, Buzzoni R, Delle Fave G, Tesselaar M, Wolin E,

Keywords: PFS, Everolimus, Lung carcinoid,